Investigation of the effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on anemia in patients with normal or mildly low glomerular filtration rate

Basit Öğe Kaydı
dc.contributor.authorErgun, Betul
dc.contributor.authorAybal Kutlugun, Ayun
dc.contributor.authorErgun, Mustafa Cagri
dc.contributor.authorAkturk, Galip
dc.contributor.authorBeyan, Esin
dc.date.accessioned2024-02-23T14:37:25Z
dc.date.available2024-02-23T14:37:25Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractBackground/aim: The relationship between the activation of the renin-angiotensin system and the increase in erythropoiesis has been shown in many studies. In addition, the use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARB) has been reported to reduce hemoglobin levels in various patient groups at risk for secondary erythrocytosis/polycythemia. The aim of our study is to investigate whether there is a change in hemoglobin levels after starting ACEIs or ARBs in patients who have not used them before. Materials and methods: Three hundred and fifty-one patients who were started on renin angiotensin aldosterone system (RAAS) blockers were evaluated retrospectively. None of the patients had anemia before starting RAAS blockers. A median of 6 (4-12) months after the start of the drug, complete blood count and kidney function tests were evaluated. Hemoglobin values before and after the start of the drug were compared statistically. Results: A statistically significant decrease in mean Hb value was found after starting ACEIs or ARBs (14.39 +/- 1.29 g/dL vs 13.98 +/- 1.36 g/dL, p < 0.001). The decrease in control Hb values was higher in the ARB group than in the ACEI group (-0.53 +/- 0.06 g/dL vs -0.29 +/- 0.06 g/dL, p < 0.001). Conclusion: A significant decrease in mean Hb level was detected in the first year following the first administration of ACEIs or ARBs.en_US
dc.identifier.doi10.3906/sag-2104-138
dc.identifier.endpage3052en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue6en_US
dc.identifier.pmid34519192en_US
dc.identifier.scopus2-s2.0-85125345295en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage3047en_US
dc.identifier.urihttps://doi.org/10.3906/sag-2104-138
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16097
dc.identifier.volume51en_US
dc.identifier.wosWOS:000731456300030en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnemiaen_US
dc.subjectHypertensionen_US
dc.subjectReninen_US
dc.subjectAngiotensinen_US
dc.subjectAldosteroneen_US
dc.titleInvestigation of the effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on anemia in patients with normal or mildly low glomerular filtration rateen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu